Abstract 90P
Background
Microtubule-targeting agents (MTAs) have been widely used as first- and second-line agents in various cancers for several decades. Furthermore, the value of MTAs is currently increasing due to their usefulness as combination drugs with immune checkpoint inhibitors. However, many development resources have been devoted to molecular-targeted agents, and the development of new MTAs has not progressed, leaving many patients struggling with the toxicity of existing MTAs. In other words, there is an urgent need to develop new microtubule inhibitors with high cancer-specificity.
Methods
Time-lapse images were taken every 2-3 minutes for 24-72 hours. Microtubules nucleated from GMPCPP-stabilized seeds were prepared and imaged using total internal reflection fluorescence (TIRF) microscopy (Ecklund KH et al. Nature Comm 2017 ). Tubulin polymerization activity, Trans-well migration assay were measured using the HTS-Tubulin Polymerization Assay Biochem Kit (Denver, CO, USA), CytoSelect 24-well cell invasion assay kits (Cell Biolabs). Orthotopic breast cancer model (MDA MB 231) and treatment - CMPD1 (i.p., 15 μg/mouse/inj, 10 times for 3 wks), Taxol (i.p., 5 mg/kg/inj, 10 times for 3 wks) were performed. Vascular invasion was identified by tumor cells within vessels in HE staining. RNAs Sequencing libraries were prepared with the TruSeq stranded mRNA kit and sequenced on NovaSeq6000 at Macrogen Japan.
Results
CMPD1, a known inhibitor of MAP kinase-activated protein kinase 2(MK2), rapidly induces microtubule depolymerization in several cancer cell-lines, resulting in robust prometaphase arrest. CMPD1 levels alter the fate of cancer cells, either inducing mitotic slippage or resulting in mitotic defects. CMPD1 inhibits microtubule polymerization and specifically induces microtubule depolymerization at the plus end in in vitro assays; resulting in significant inhibition of tumor growth, cancer cell migration, and invasion in both in vitro and in vivo. Furthermore, clinically relevant low doses of CMPD1 induced severe and prolonged mitotic failure specifically in cancer cells, but not in non-transformed cells, with only modest effects on microtubules in vitro.
Conclusions
CMPD1 has the potential to serve as a cancer cell-selective MTA chemotherapeutic agent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI 21K08638.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09